Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project.

IF 5.6 2区 医学 Q1 ONCOLOGY JCO precision oncology Pub Date : 2025-02-01 Epub Date: 2025-02-12 DOI:10.1200/PO-24-00675
Martina Haberecker, Jan H Rüschoff, Charitini Andriakopoulou, Steven G Gray, Kristiaan Nackaerts, Marc De Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Luca Ampollini, Joachim G Aerts, Michaela B Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samarzija, Roger Llatjos, Stephen P Finn, Enrico Silini, Jan Von Der Thüsen, Patrick Vagenknecht, Zoi Tsourti, Keith M Kerr, Roswitha Kammler, Solange Peters, Paul Baas, Isabelle Opitz, Rolf A Stahel, Alessandra Curioni-Fontecedro
{"title":"Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project.","authors":"Martina Haberecker, Jan H Rüschoff, Charitini Andriakopoulou, Steven G Gray, Kristiaan Nackaerts, Marc De Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Luca Ampollini, Joachim G Aerts, Michaela B Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samarzija, Roger Llatjos, Stephen P Finn, Enrico Silini, Jan Von Der Thüsen, Patrick Vagenknecht, Zoi Tsourti, Keith M Kerr, Roswitha Kammler, Solange Peters, Paul Baas, Isabelle Opitz, Rolf A Stahel, Alessandra Curioni-Fontecedro","doi":"10.1200/PO-24-00675","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>CD276 (B7-H3) is an immunoregulatory protein that plays an important role in the inhibition of T-cell function. CD276 is overexpressed on a variety of human solid cancer cells with limited expression in normal tissues, making it an appealing target for innovative cancer immunotherapy approaches. Pleural mesothelioma (PM) is a highly aggressive disease with a need for new treatment options. Our objective was to investigate the expression of CD276 in the multicenter PM cohort of the European Thoracic Oncology Platform Mesoscape project and correlate the results with annotated clinical data.</p><p><strong>Materials and methods: </strong>Using tissue microarrays (TMAs), the expression of CD276, assessed using a semiquantitative aggregate <i>H</i>-score method on the membrane (and secondarily in the cytoplasm), was correlated with clinicopathologic characteristics and survival outcome.</p><p><strong>Results: </strong>CD276 immunohistochemistry results were available for 353 patients, with mostly epithelioid histology (71%). Membranous CD276 expression was present in 86%. High membranous CD276 expression (<i>H</i>-score ≥the median <i>H</i>-score of 120) was significantly more common in females (<i>P</i> = .0029; 71% <i>v</i> 47%) and in epithelioid histology (<i>P</i> < .001; 59% <i>v</i> 29%), whereas no significant association in clinical outcome (overall survival [OS]/progression-free survival) was found. Cross-validation of the TMA method using whole sections revealed a moderate agreement for membranous assessment (Cohen's kappa = 0.47) and a lower agreement for cytoplasm assessment (Cohen's kappa = 0.37). In an exploratory analysis, high cytoplasmic CD276 expression was associated with worse prognosis (OS, log-rank <i>P</i> = .043), but was not significant when adjusting for other clinical variables.</p><p><strong>Conclusion: </strong>Although no prognostic value of CD276 expression was found, its high membranous expression (86%) in the PM samples of the study supports further research of its potential as a therapeutic target for this disease.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"9 ","pages":"e2400675"},"PeriodicalIF":5.6000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO precision oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/PO-24-00675","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: CD276 (B7-H3) is an immunoregulatory protein that plays an important role in the inhibition of T-cell function. CD276 is overexpressed on a variety of human solid cancer cells with limited expression in normal tissues, making it an appealing target for innovative cancer immunotherapy approaches. Pleural mesothelioma (PM) is a highly aggressive disease with a need for new treatment options. Our objective was to investigate the expression of CD276 in the multicenter PM cohort of the European Thoracic Oncology Platform Mesoscape project and correlate the results with annotated clinical data.

Materials and methods: Using tissue microarrays (TMAs), the expression of CD276, assessed using a semiquantitative aggregate H-score method on the membrane (and secondarily in the cytoplasm), was correlated with clinicopathologic characteristics and survival outcome.

Results: CD276 immunohistochemistry results were available for 353 patients, with mostly epithelioid histology (71%). Membranous CD276 expression was present in 86%. High membranous CD276 expression (H-score ≥the median H-score of 120) was significantly more common in females (P = .0029; 71% v 47%) and in epithelioid histology (P < .001; 59% v 29%), whereas no significant association in clinical outcome (overall survival [OS]/progression-free survival) was found. Cross-validation of the TMA method using whole sections revealed a moderate agreement for membranous assessment (Cohen's kappa = 0.47) and a lower agreement for cytoplasm assessment (Cohen's kappa = 0.37). In an exploratory analysis, high cytoplasmic CD276 expression was associated with worse prognosis (OS, log-rank P = .043), but was not significant when adjusting for other clinical variables.

Conclusion: Although no prognostic value of CD276 expression was found, its high membranous expression (86%) in the PM samples of the study supports further research of its potential as a therapeutic target for this disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CD276 (B7-H3)在胸膜间皮瘤中的表达及其临床相关性:来自欧洲胸廓平台间皮瘤项目的结果
目的:CD276 (B7-H3)是一种免疫调节蛋白,在抑制t细胞功能中起重要作用。CD276在多种人类实体癌细胞上过表达,而在正常组织中表达有限,这使其成为创新癌症免疫治疗方法的一个有吸引力的靶点。胸膜间皮瘤(PM)是一种高度侵袭性疾病,需要新的治疗方案。我们的目的是研究CD276在欧洲胸肿瘤平台messcape项目的多中心PM队列中的表达,并将结果与注释的临床数据联系起来。材料和方法:使用组织微阵列(TMAs),使用半定量聚集h评分法评估膜(其次是细胞质)上CD276的表达与临床病理特征和生存结果相关。结果:353例患者获得CD276免疫组化结果,大部分为上皮样组织学(71%)。86%的患者膜性表达CD276。膜性CD276高表达(H-score≥中位H-score 120)在女性中更为常见(P = 0.0029;71% vs 47%)和上皮样组织学差异(P < 0.001;59% vs 29%),而临床结果(总生存期[OS]/无进展生存期)无显著相关性。使用全切片对TMA方法进行交叉验证,发现膜性评估的一致性中等(Cohen’s kappa = 0.47),细胞质评估的一致性较低(Cohen’s kappa = 0.37)。在一项探索性分析中,高细胞质CD276表达与较差的预后相关(OS, log-rank P = 0.043),但在调整其他临床变量时,这一相关性不显著。结论:虽然没有发现CD276表达的预后价值,但其在本研究PM样品中的高膜性表达(86%)支持其作为该疾病治疗靶点的潜力的进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.10
自引率
4.30%
发文量
363
期刊最新文献
Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment. Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer. Longitudinal, Retrospective Use of a Circulating Tumor DNA Methylation Signature Successfully Captures Small Cell Evolution in a Patient With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer. Circulating Tumor DNA Monitoring in Peptide Receptor Radionuclide Therapy-Treated Patients With Gastroenteropancreatic Neuroendocrine Tumors. Clinical Response to Poly(ADP-ribose) Polymerase Inhibitor in Metastatic Breast Cancer With a Germline Reduced-Penetrance BRCA2 Pathogenic Variant: A Molecular Tumor Board Discussion.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1